Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal
Abstract Background Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP...
Gespeichert in:
Veröffentlicht in: | Contraception (Stoneham) 2014-05, Vol.89 (5), p.361-367 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 367 |
---|---|
container_issue | 5 |
container_start_page | 361 |
container_title | Contraception (Stoneham) |
container_volume | 89 |
creator | Burke, Holly M Mueller, Monique P Perry, Brian Packer, Catherine Bufumbo, Leonard Mbengue, Daouda Mall, Ibrahima Daff, Bocar Mamadou Mbonye, Anthony K |
description | Abstract Background Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP's acceptability is unknown. We measured acceptability of SP among DMPA IM users. Study design This open-label observational study was conducted in clinics in three districts in Senegal and community-based distribution services in two districts in Uganda. Experienced DMPA IM users were offered SP by community health workers (CHWs) or clinic-based providers. SP decliners were asked to discuss their reasons. Those who received SP were interviewed pre- and postinjection and 3 months later, when they were asked if they would select SP over DMPA IM if it were available. Results One hundred twenty women in Uganda and 242 in Senegal received SP (117 and 240 were followed up, respectively). Nine Ugandan and seven Senegalese SP decliners were interviewed. Three months after receiving SP, 84% [95% confidence interval (CI)=75%–93%] of Ugandan participants and 80% (95% CI=74%–87%) of Senegalese participants said they would select SP over DMPA IM. Main reasons for selecting SP were fewer side effects, liking the method, fast administration, less pain and method effectiveness. Thirty-four adverse events were reported but were not serious. No pregnancies were reported. Conclusion Current DMPA IM users in Senegal and Uganda accepted SP, and most preferred SP over DMPA IM. SP can be safely introduced into FP programs and administered by trained CHWs, with expectation of client uptake. Implications We found SP acceptable and safe in diverse settings among current intramuscular DMPA users, including those who received SP from CHWs. This provides evidence that SP would be used and could therefore reduce unmet family planning needs if introduced into family planning programs. |
doi_str_mv | 10.1016/j.contraception.2014.01.022 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1524177062</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010782414000328</els_id><sourcerecordid>1524177062</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-7aa14ca04efff224e89ad3f0e01d12561eda0c5ebce73335b74a414a50a406123</originalsourceid><addsrcrecordid>eNqNkt-K1DAUh4Mo7uzqK0hABG9aT9Kk7SAIy7r-gZVdGPc6nKanY8ZOMybtwryUD7FPZuqMil55k0Dy5XcOXw5jzwXkAkT5apNbP4wBLe1G54dcglA5iBykfMAWoq6WGWhRP2QLAAFZVUt1wk5j3ABAtdTVY3YiVVmIQtYL5q-bSOEO5yTseRynds99x8cvxNHOJbBxvRt_Hq5wjwPef-c3gWLkuPXDmru5l-0U7dRj4G8_3ZzzKUXGdMFv1zi0yNPCVzTQGvsn7FGHfaSnx_2M3b67_HzxIbu6fv_x4vwqs6qsx6xCFMoiKOq6TkpF9RLbogMC0QqpS0EtgtXUWKqKotBNpVAJhRpQQSlkccZeHnJ3wX-bKI5m66KlvseB_BSN0FKJqoJyRl8fUBt8jIE6swtui2FvBJjZuNmYv4yb2bgBYZLx9PrZsdDUbKn9_faX4gS8OAIYLfZdwMG6-IerdaGVhsRdHjhKWu4cBROto8FS6wLZ0bTe_WdDb_7Jsb0bXCr9lfYUN34K6aeTAROlAbOah2SeEaHSfMwN_wAmlL1e</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1524177062</pqid></control><display><type>article</type><title>Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Burke, Holly M ; Mueller, Monique P ; Perry, Brian ; Packer, Catherine ; Bufumbo, Leonard ; Mbengue, Daouda ; Mall, Ibrahima ; Daff, Bocar Mamadou ; Mbonye, Anthony K</creator><creatorcontrib>Burke, Holly M ; Mueller, Monique P ; Perry, Brian ; Packer, Catherine ; Bufumbo, Leonard ; Mbengue, Daouda ; Mall, Ibrahima ; Daff, Bocar Mamadou ; Mbonye, Anthony K</creatorcontrib><description>Abstract Background Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP's acceptability is unknown. We measured acceptability of SP among DMPA IM users. Study design This open-label observational study was conducted in clinics in three districts in Senegal and community-based distribution services in two districts in Uganda. Experienced DMPA IM users were offered SP by community health workers (CHWs) or clinic-based providers. SP decliners were asked to discuss their reasons. Those who received SP were interviewed pre- and postinjection and 3 months later, when they were asked if they would select SP over DMPA IM if it were available. Results One hundred twenty women in Uganda and 242 in Senegal received SP (117 and 240 were followed up, respectively). Nine Ugandan and seven Senegalese SP decliners were interviewed. Three months after receiving SP, 84% [95% confidence interval (CI)=75%–93%] of Ugandan participants and 80% (95% CI=74%–87%) of Senegalese participants said they would select SP over DMPA IM. Main reasons for selecting SP were fewer side effects, liking the method, fast administration, less pain and method effectiveness. Thirty-four adverse events were reported but were not serious. No pregnancies were reported. Conclusion Current DMPA IM users in Senegal and Uganda accepted SP, and most preferred SP over DMPA IM. SP can be safely introduced into FP programs and administered by trained CHWs, with expectation of client uptake. Implications We found SP acceptable and safe in diverse settings among current intramuscular DMPA users, including those who received SP from CHWs. This provides evidence that SP would be used and could therefore reduce unmet family planning needs if introduced into family planning programs.</description><identifier>ISSN: 0010-7824</identifier><identifier>EISSN: 1879-0518</identifier><identifier>DOI: 10.1016/j.contraception.2014.01.022</identifier><identifier>PMID: 24631328</identifier><identifier>CODEN: CCPTAY</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Biological and medical sciences ; Community health worker ; Contraception ; Contraceptive Agents, Female - administration & dosage ; Depot medroxyprogesterone acetate ; Female ; Genital system. Reproduction ; Gynecology. Andrology. Obstetrics ; Humans ; Injections, Subcutaneous ; Medical sciences ; Medroxyprogesterone Acetate - administration & dosage ; Obstetrics and Gynecology ; Patient Acceptance of Health Care - statistics & numerical data ; Pharmacology. Drug treatments ; Senegal ; Subcutaneous injection ; Uganda ; Young Adult</subject><ispartof>Contraception (Stoneham), 2014-05, Vol.89 (5), p.361-367</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-7aa14ca04efff224e89ad3f0e01d12561eda0c5ebce73335b74a414a50a406123</citedby><cites>FETCH-LOGICAL-c468t-7aa14ca04efff224e89ad3f0e01d12561eda0c5ebce73335b74a414a50a406123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.contraception.2014.01.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28535450$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24631328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burke, Holly M</creatorcontrib><creatorcontrib>Mueller, Monique P</creatorcontrib><creatorcontrib>Perry, Brian</creatorcontrib><creatorcontrib>Packer, Catherine</creatorcontrib><creatorcontrib>Bufumbo, Leonard</creatorcontrib><creatorcontrib>Mbengue, Daouda</creatorcontrib><creatorcontrib>Mall, Ibrahima</creatorcontrib><creatorcontrib>Daff, Bocar Mamadou</creatorcontrib><creatorcontrib>Mbonye, Anthony K</creatorcontrib><title>Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal</title><title>Contraception (Stoneham)</title><addtitle>Contraception</addtitle><description>Abstract Background Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP's acceptability is unknown. We measured acceptability of SP among DMPA IM users. Study design This open-label observational study was conducted in clinics in three districts in Senegal and community-based distribution services in two districts in Uganda. Experienced DMPA IM users were offered SP by community health workers (CHWs) or clinic-based providers. SP decliners were asked to discuss their reasons. Those who received SP were interviewed pre- and postinjection and 3 months later, when they were asked if they would select SP over DMPA IM if it were available. Results One hundred twenty women in Uganda and 242 in Senegal received SP (117 and 240 were followed up, respectively). Nine Ugandan and seven Senegalese SP decliners were interviewed. Three months after receiving SP, 84% [95% confidence interval (CI)=75%–93%] of Ugandan participants and 80% (95% CI=74%–87%) of Senegalese participants said they would select SP over DMPA IM. Main reasons for selecting SP were fewer side effects, liking the method, fast administration, less pain and method effectiveness. Thirty-four adverse events were reported but were not serious. No pregnancies were reported. Conclusion Current DMPA IM users in Senegal and Uganda accepted SP, and most preferred SP over DMPA IM. SP can be safely introduced into FP programs and administered by trained CHWs, with expectation of client uptake. Implications We found SP acceptable and safe in diverse settings among current intramuscular DMPA users, including those who received SP from CHWs. This provides evidence that SP would be used and could therefore reduce unmet family planning needs if introduced into family planning programs.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Community health worker</subject><subject>Contraception</subject><subject>Contraceptive Agents, Female - administration & dosage</subject><subject>Depot medroxyprogesterone acetate</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Medical sciences</subject><subject>Medroxyprogesterone Acetate - administration & dosage</subject><subject>Obstetrics and Gynecology</subject><subject>Patient Acceptance of Health Care - statistics & numerical data</subject><subject>Pharmacology. Drug treatments</subject><subject>Senegal</subject><subject>Subcutaneous injection</subject><subject>Uganda</subject><subject>Young Adult</subject><issn>0010-7824</issn><issn>1879-0518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkt-K1DAUh4Mo7uzqK0hABG9aT9Kk7SAIy7r-gZVdGPc6nKanY8ZOMybtwryUD7FPZuqMil55k0Dy5XcOXw5jzwXkAkT5apNbP4wBLe1G54dcglA5iBykfMAWoq6WGWhRP2QLAAFZVUt1wk5j3ABAtdTVY3YiVVmIQtYL5q-bSOEO5yTseRynds99x8cvxNHOJbBxvRt_Hq5wjwPef-c3gWLkuPXDmru5l-0U7dRj4G8_3ZzzKUXGdMFv1zi0yNPCVzTQGvsn7FGHfaSnx_2M3b67_HzxIbu6fv_x4vwqs6qsx6xCFMoiKOq6TkpF9RLbogMC0QqpS0EtgtXUWKqKotBNpVAJhRpQQSlkccZeHnJ3wX-bKI5m66KlvseB_BSN0FKJqoJyRl8fUBt8jIE6swtui2FvBJjZuNmYv4yb2bgBYZLx9PrZsdDUbKn9_faX4gS8OAIYLfZdwMG6-IerdaGVhsRdHjhKWu4cBROto8FS6wLZ0bTe_WdDb_7Jsb0bXCr9lfYUN34K6aeTAROlAbOah2SeEaHSfMwN_wAmlL1e</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Burke, Holly M</creator><creator>Mueller, Monique P</creator><creator>Perry, Brian</creator><creator>Packer, Catherine</creator><creator>Bufumbo, Leonard</creator><creator>Mbengue, Daouda</creator><creator>Mall, Ibrahima</creator><creator>Daff, Bocar Mamadou</creator><creator>Mbonye, Anthony K</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140501</creationdate><title>Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal</title><author>Burke, Holly M ; Mueller, Monique P ; Perry, Brian ; Packer, Catherine ; Bufumbo, Leonard ; Mbengue, Daouda ; Mall, Ibrahima ; Daff, Bocar Mamadou ; Mbonye, Anthony K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-7aa14ca04efff224e89ad3f0e01d12561eda0c5ebce73335b74a414a50a406123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Community health worker</topic><topic>Contraception</topic><topic>Contraceptive Agents, Female - administration & dosage</topic><topic>Depot medroxyprogesterone acetate</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Medical sciences</topic><topic>Medroxyprogesterone Acetate - administration & dosage</topic><topic>Obstetrics and Gynecology</topic><topic>Patient Acceptance of Health Care - statistics & numerical data</topic><topic>Pharmacology. Drug treatments</topic><topic>Senegal</topic><topic>Subcutaneous injection</topic><topic>Uganda</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burke, Holly M</creatorcontrib><creatorcontrib>Mueller, Monique P</creatorcontrib><creatorcontrib>Perry, Brian</creatorcontrib><creatorcontrib>Packer, Catherine</creatorcontrib><creatorcontrib>Bufumbo, Leonard</creatorcontrib><creatorcontrib>Mbengue, Daouda</creatorcontrib><creatorcontrib>Mall, Ibrahima</creatorcontrib><creatorcontrib>Daff, Bocar Mamadou</creatorcontrib><creatorcontrib>Mbonye, Anthony K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Contraception (Stoneham)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burke, Holly M</au><au>Mueller, Monique P</au><au>Perry, Brian</au><au>Packer, Catherine</au><au>Bufumbo, Leonard</au><au>Mbengue, Daouda</au><au>Mall, Ibrahima</au><au>Daff, Bocar Mamadou</au><au>Mbonye, Anthony K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal</atitle><jtitle>Contraception (Stoneham)</jtitle><addtitle>Contraception</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>89</volume><issue>5</issue><spage>361</spage><epage>367</epage><pages>361-367</pages><issn>0010-7824</issn><eissn>1879-0518</eissn><coden>CCPTAY</coden><abstract>Abstract Background Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP's acceptability is unknown. We measured acceptability of SP among DMPA IM users. Study design This open-label observational study was conducted in clinics in three districts in Senegal and community-based distribution services in two districts in Uganda. Experienced DMPA IM users were offered SP by community health workers (CHWs) or clinic-based providers. SP decliners were asked to discuss their reasons. Those who received SP were interviewed pre- and postinjection and 3 months later, when they were asked if they would select SP over DMPA IM if it were available. Results One hundred twenty women in Uganda and 242 in Senegal received SP (117 and 240 were followed up, respectively). Nine Ugandan and seven Senegalese SP decliners were interviewed. Three months after receiving SP, 84% [95% confidence interval (CI)=75%–93%] of Ugandan participants and 80% (95% CI=74%–87%) of Senegalese participants said they would select SP over DMPA IM. Main reasons for selecting SP were fewer side effects, liking the method, fast administration, less pain and method effectiveness. Thirty-four adverse events were reported but were not serious. No pregnancies were reported. Conclusion Current DMPA IM users in Senegal and Uganda accepted SP, and most preferred SP over DMPA IM. SP can be safely introduced into FP programs and administered by trained CHWs, with expectation of client uptake. Implications We found SP acceptable and safe in diverse settings among current intramuscular DMPA users, including those who received SP from CHWs. This provides evidence that SP would be used and could therefore reduce unmet family planning needs if introduced into family planning programs.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>24631328</pmid><doi>10.1016/j.contraception.2014.01.022</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0010-7824 |
ispartof | Contraception (Stoneham), 2014-05, Vol.89 (5), p.361-367 |
issn | 0010-7824 1879-0518 |
language | eng |
recordid | cdi_proquest_miscellaneous_1524177062 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adult Biological and medical sciences Community health worker Contraception Contraceptive Agents, Female - administration & dosage Depot medroxyprogesterone acetate Female Genital system. Reproduction Gynecology. Andrology. Obstetrics Humans Injections, Subcutaneous Medical sciences Medroxyprogesterone Acetate - administration & dosage Obstetrics and Gynecology Patient Acceptance of Health Care - statistics & numerical data Pharmacology. Drug treatments Senegal Subcutaneous injection Uganda Young Adult |
title | Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A47%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Observational%20study%20of%20the%20acceptability%20of%20Sayana%C2%AE%20Press%20among%20intramuscular%20DMPA%20users%20in%20Uganda%20and%20Senegal&rft.jtitle=Contraception%20(Stoneham)&rft.au=Burke,%20Holly%20M&rft.date=2014-05-01&rft.volume=89&rft.issue=5&rft.spage=361&rft.epage=367&rft.pages=361-367&rft.issn=0010-7824&rft.eissn=1879-0518&rft.coden=CCPTAY&rft_id=info:doi/10.1016/j.contraception.2014.01.022&rft_dat=%3Cproquest_cross%3E1524177062%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1524177062&rft_id=info:pmid/24631328&rft_els_id=S0010782414000328&rfr_iscdi=true |